Reviewed on 3/10/2022

Generic Name: Alirocumab

Brand Name: Praluent

Drug Class: Lipid-Lowering Agents, PCSK9 Inhibitors

What Is Alirocumab and How Does It Work?

Alirocumab is a prescription medication used for the treatment of hyperlipidemia, thereby reducing the risk of cardiovascular diseases.

  • Alirocumab is available under the following different brand names: Praluent

What Are Dosages of Alirocumab?

Adult dosage

Injection, solution

Prefilled, single-dose pen for SC injection

  • 75mg/mL
  • 150mg/mL

Hyperlipidemia Treatment and/or CV Risk Reduction

Adult dosage

  • Established CV disease or primary hyperlipidemia, including HeFH
    • 75 mg SC every 2 weeks or 300 mg SC every 4 weeks initially
    • For patients on 300 mg every 4 weeks, measure LDL-C just before the next scheduled dose; LDL-C can vary between doses in some patients
    • If LDL-C response is inadequate,  may adjust dose by 150 mg SC every 2 weeks
  • Patients with HeFH undergoing apheresis or with HoFH
    • 150 mg SC every 2 weeks
    • May be administered without regard to timing of apheresis

Dosage Considerations – Should be Given as Follows: 

  • See “Dosages”

What Are Side Effects Associated with Using Alirocumab?

Common side effects of Alirocumab include:

Serious side effects of Alirocumab include:

  • none.

Rare side effects of Alirocumab include:

  • none 
This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.


How to Lower Your Cholesterol & Save Your Heart See Slideshow

What Other Drugs Interact with Alirocumab?

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

  • Alirocumab has no noted severe interactions with any other drugs.
  • Alirocumab has no noted serious interactions with any other drugs.
  • Alirocumab has no noted moderate interactions with any other drugs.
  • Alirocumab has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns.

What Are Warnings and Precautions for Alirocumab?


  • History of serious hypersensitivity reaction to alirocumab or its excipients; reactions have included hypersensitivity vasculitis, angioedema, and hypersensitivity reactions requiring hospitalization

Effects of drug abuse

  • None

Short-Term Effects

  • See “What Are Side Effects Associated with Using Alirocumab?”

Long-Term Effects

  • See “What Are Side Effects Associated with Using Alirocumab?”


  • Hypersensitivity reactions (eg, pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported; discontinue and treat if signs or symptoms of serious allergic reactions occur

Pregnancy and Lactation

  • Available data from clinical trials and postmarketing reports in pregnant females are insufficient to evaluate for drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
  • There is a pregnancy safety study if administered during pregnancy; report exposure (1-844-734-6643).
  • Lactation
    • Unknown if distributed in human breast milk
    • The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant
    • Human IgG is present in human milk, but published data suggest that breastmilk IgG antibodies do not enter the neonatal and infant circulation in substantial amounts
Medscape. Alirocumab.

Health Solutions From Our Sponsors